– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and COPD – – Program updates also include completion of enrollment in Phase 2 clinical trial in severe asthma; top-line data now expected in first qu ...

文章核心观点 - 上游生物公司公布的转化药理学建模数据支持维瑞库图单抗（verekitug）靶向胸腺基质淋巴细胞生成素（TSLP）受体的机制，相比靶向TSLP配体的疗法更有效力，有望在多种炎症性疾病中展现差异化优势 [1] 关于TSLP和TSLPR阻断 - TSLP是主要过敏性和炎症性疾病炎症反应的关键驱动因子，阻断TSLP信号已被临床验证为有效治疗策略 [2][5] - TSLP激活是炎症级联反应的早期事件，阻断TSLP受体可让单一疗法影响多种疾病的病理炎症过程 [6][7] 关于维瑞库图单抗 - 维瑞库图单抗是新型重组全人免疫球蛋白G1单克隆抗体，是目前唯一处于临床开发阶段、靶向并抑制TSLP受体的单克隆抗体 [2][8] - 维瑞库图单抗正在两项多国、安慰剂对照、随机2期临床试验中评估，还计划开展慢性阻塞性肺疾病（COPD）的2期临床试验 [8] - 临床前研究中，维瑞库图单抗显示出对TSLP受体的高占有率和对TSLP信号的强效抑制，还能抑制细胞因子产生并完全抑制皮肤过敏反应 [9] - 三项维瑞库图单抗临床试验已完成，该药耐受性良好，无临床显著免疫原性，药代动力学特征可预测且一致，皮下生物利用度高 [10] 建模数据总结 - 采用半机制药代动力学/药效学（PK/PD）模型，使用相同生物和药物参数，结合维瑞库图单抗观察数据和替泽珠单抗（tezepelumab）已发表数据 [6] - PK/PD模型模拟显示，在一系列剂量下，维瑞库图单抗相比替泽珠单抗能更完全、持续地抑制TSLP/TSLPR复合物 [6] - 剂量反应模型模拟表明，对TSLP/TSLPR复合物的强效抑制会使呼出气一氧化氮分数（FeNO）更大幅度降低 [6] - 建模数据显示，维瑞库图单抗使FeNO降低幅度更大，可能是因为TSLP受体表达水平随时间降低、蛋白周转时间较慢 [6] - 这些数据表明，维瑞库图单抗靶向TSLP受体的差异化机制可能带来比靶向TSLP配体更强的效力 [6] 公司情况 - 上游生物是临床阶段生物技术公司，专注开发炎症性疾病疗法，尤其关注严重呼吸系统疾病 [1][11] - 公司正在推进维瑞库图单抗在严重哮喘、慢性鼻-鼻窦炎伴鼻息肉（CRSwNP）的2期试验，并启动COPD开发 [11] - 公司医学官期待评估维瑞库图单抗独特机制转化为临床益处的潜力，先关注今年三季度CRSwNP的2期临床数据，再关注2026年上半年严重哮喘的数据 [3]

WALTHAM, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical- stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced an upcoming presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025 in Glasgow, UK, on Sunday, June 15, 2025. The presentation features translational pharmacology modeling data that supports Thymic Stromal Lymphopoietin (TSLP) receptor targetin ...

A live webcast of the fireside chat will be available under the "Events" tab on the "Investors" page of the Company's website on the day of the event. A replay of the webcast will be posted on the Company's website following the presentation. WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical- stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executi ...

About Upstream Bio Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin, a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. ...